Protocol Ledger

NCT06627179 · Phase II · ACTIVE NOT RECRUITING

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Interventional Phase II clinical trial protocol NCT06627179 sponsored by Laboratoires Thea in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-11 Enrollment: 81 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06627179
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)81 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06627179
Protocol FieldVerified Registry Value
NCT IdentifierNCT06627179
Consolidated Lead SponsorLaboratoires Thea
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment81 participants (ESTIMATED)
Registered Start Date2024-12-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI